Nonapprovable letter to Allergan

Share this article:
The FDA has issued a nonapprovable letter to Allergan for tazarotene capsules (oral tazarotene) for the treatment of psoriasis.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.